Victoria L. Peek

Eli Lilly (United States) — United States

Medicine · Health Sciences

8h-index647citations52works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver physiology and pathology(23), Cancer Mechanisms and Therapy(19), PI3K/AKT/mTOR signaling in cancer(11), Hepatocellular Carcinoma Treatment and Prognosis(9), Cancer, Hypoxia, and Metabolism(8)

Publications52 total

Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules
The AAPS Journal·2025
Cross-Reactive Polyclonal Antibodies Raised Against GalNAc-Conjugated siRNA Recognize Mostly the GalNAc Moiety
The AAPS Journal·2024· 2 cited
A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog
Journal of Immunological Methods·2023· 8 cited
Data from LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
2023Open Access
Data from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
Supplementary Table S3 from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
Supplementary Figures from LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
2023Open Access
Supplementary Figure Legend from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
Supplementary Table S2 from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
Supplementary Table S3 from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
Supplementary Tables from LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
2023Open Access
Supplementary Table S1 from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
Supplementary Table S2 from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
Supplementary Figure S1 from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
Supplementary Methods and Figure Legends from LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
2023Open Access
Supplementary Figures from LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
2023Open Access
Supplementary Figure S1 from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
Supplementary Figure Legend from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
Data from LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
2023Open Access
Supplementary Materials and Methods from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Kelly M. Credille(30), Jason R. Manro(29), Richard A. Walgren(24), S. Betty Yan(19), Jennifer R. Stephens(19), Gregory P. Donoho(15), Suzane L. Um(14), Mark A. Wortinger(14), Darryl Ballard(14), Peter Vaillancourt(14), Jirong Lu(14), John A. Wijsman(14), Chi-Kin Chow(13), S. Betty Yan(13), Jonathan W. Tetreault(12), Jinqi Xia(12), Volker Wacheck(11), Irene Denning(11), Wenjuan Wu(10), Bruce W. Konicek(9)